Cancer drug for Bioglan

Bioglan Pharma, the British pharmaceutical company with an Irish stock exchange quotation, has entered into a licensing agreement for Solarase in several European countries. Solarase is a treatment for actinic keratoses, a potentially pre-cancerous skin condition. Under the agreement, SkyePharma will grant Bioglan an exclusive licence for the manufacture, marketing, sale and distribution of the product in the EU. In return, Bioglan will pay a licence fee on signing and royalties on the sales of the product.